Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jim re your comment ,
I thought the original indication for Mevacor was for secondary prevention. I believe the West of Scotland study with Pravastatin was what gave way for the primary prevention indication.
MK,
https://clinicaltrials.gov/study/NCT04239950?term=Vascepa&page=2&rank=12
This is the study that is being conducted in China. It looks like Mochida is interested in selling Epadol in China. Both Amarin and Mochida have their own partners in China.
Sleven,
I am confused, is Mochida a Partner with AMRN in China or is this Epadel formula separate from AMRN? Would appreciate anyone who can clarify, please. Thx.
Whal, I thought the original indication for Mevacor was for secondary prevention. I believe the West of Scotland study with Pravastatin was what gave way for the primary prevention indication. Lipitor, in my opinion has the worst SE profile. Rosuvastatin (Crestor) would be my choice. With an LDL of 160 (thanks mom) I began taking a statin. I had trouble with Lipitor and then moved to Pravachol. In the end, I quit altogether, feeling somewhat protected with an HDL of 70 (thanks mom). Mom's LDL was in the 160 range also, but with an HDL of 120! She's 92 now). Strangely (not really, I was drinking nothing but filtered water, using table salt, had a whole house water filter, not. getting minerals), in my mid 40's I developed proximal afib, then eventually permanent afib. While researching a cure, I found a liquid form of magnesium, I believe they refer to it as pico ionic. Anyway, I took the BID dosed magnesium, regardless of taste. It did not alleviate the Afib, so I went in for ablation. That was 7 years ago and no reoccurrence, which is typically 50%. With 70% of the country having magnesium deficiency, I continue to take a QD dose. But here's the kicker! After a few months, I went in for a Wellcheck. My LDL dropped from 160 to 129, no meds. Still there today. Back pain (which I'd struggled with for years, despite exercising/stretching 5 days/wk) is absolutely gone. Muscle strength, lung capacity too were much improved. Astounded, I read up on what exactly Mg does. Runs over 70 or so enzymatic processes in the body. It appears it is literally a natural (HMG-CoA) reductase inhibitor, but also huge for muscle repair and function, etc., etc. Read up on Magnesium, it's amazing. Lastly, even though your blood work will show normal Mg levels, you could be and probably are deficient. Why? The test just measures systemically, what's in the blood. Our organs, muscles, when deficient rely on our blood to rob from the areas of abundance, distributing the areas of need. The blood will show normal, even thought the heart, major muscle groups are deficient. I asked my CD "why the test if it isn't a true measure?" He said it just part of the panel. WTF. There is a legitimate test for Magnesium, but you'll end up paying for it. Corrupt medicine. Also figured out docs don't work through using Magnesium on patients. Too difficult, tastes bad, uncomfortable side effects in the beginning.....but the body adjusts! Good luck, you have to do your own research to make informed decisions WITH your MD regarding your health, because they'll do the quickest and easiest treatment.
Caddie ...After approval of the Marine indication mid 2012 the Ceo at the time floated 3 options ...sell the co , partner with a BP or GIA ( go it alone ) .
12 weeks went by as the Ceo ( Z ) explored these options and when no buyer or partner emerged they announced GIA and the stock tanked.
Kiwi
There were BO rumors in October of ‘12 (that’s when I first bought in) and it went from $11 to $14 but was “Z” really trying to sell 12 years ago? How does anyone really know or verify M&A until it actually happens
zip…again, why no credible offer (credible offer would have to be taken to shareholders and disclosed) in 10 years…..Z was trying to sell, his successor was open to offer, the prior Board was motivated to sell during proxy contest (to save embarrassment of getting voted out)…not even credible low ball offer……why?
RMB, I believe Meiji Seika Pharma has the marketing rights for Epadel in China. That was announced in April.
Not sure about approvals and reimbursement yet.
RMB, Mochida was apparently required to conduct a clinical trial in China. Same as Amarin. That trial has not been updated for some time. I haven't seen any information about a commercial launch.
Sleven,
Sleven, I did dig up that link as well showing the start of clinical trials. But no info about results or if it is being reimbursed in China. This is what Tats posted:
https://pj.jiho.jp/article/250727
I guess to Kiwi's point, the Generics don't have a CVD indication here in the States but are still getting a bunch of sales.
It's China ...it doesn't matter . They will rip it off anyway
Kiwi
Kiwi, No CVD indication.
Sleven,
Yep and it'll be a lot less expensive than Vascepa .
Meanwhile we await Denner/ Holts grand plan for cracking the remaining big 3 EU market ...where they at least have patent protection .
Kiwi
JRoon, Zip, a question about China. A couple of days ago I believe Tats posted a link that described where Epadel was going to be marketed in China. There was a paywall and I also could not find more info about it elsewhere. My question is whether Epadel already has reimbursement, or is just an over the counter there? Would it be competition for V?
zip, I hope the Denner, Holt team - makes themself visible (knocks the door) at Novo Nordisk - the European Pharma Company that is absolutely flying for the moment.
Some poster here - a few weeks back argued brilliantly 'why Amarin CDV fighting drug Vascepa / Vazkepa' - will fit perfectly into an area were NOVO right now can improve in their sortiment of successful drugs 🙂
Great points, Zip.
I think these are the most critical for a buyer:
-Potential buyers are waiting to see more European approvals for the sale of Vascepa
-Buyers want to know about what European National Health Services will be willing to pay for Vascepa
-The same holds true for China
No worries, Jasbg. I appreciate the post.
Thanks Sleven. I've used that site before (I think when snooping around for MITIGATE results), and one thing I noticed is that some trials still miss their reporting deadlines. But assuming all is well with the study, it seems that they should be reporting prior to CTAD.
Amarin is definitely for sale...some of the reasons the sale is being delayed are...
-The current price tag is presently too high
-Potential buyers are waiting to see more European approvals for the sale of Vascepa
-Buyers want to know about what European National Health Services will be willing to pay for Vascepa
-The same holds true for China
-Buyers want to see increased revenues before they agree to the prices being asked, which are far above the present market price
-Buyers are still awaiting more good news about other potential new indications for Vascepa
IMO the sale will occur...It's not if, but when!
A Nasdaq-listed company will receive a deficiency notice if its stock trades below $1 per share for 30 consecutive business days.
The company then has 180 calendar days to regain compliance by maintaining a minimum $1 closing bid price for at least 10 consecutive business days.
Amazing new Opportunity for AMARIN. AS you will recall in 2007 AMRN stock was at about $1. The desperate housewive of INvestors Hub were jilted bY the Loser Thero who absconded with most of their money. They then fell in love with the CAD AMRN who continually pumps and dumps them yet they ALWAYS come back for more. SO has the story changed ? ROFLMAO - !!
The Fat Lady is singing in the kitchen while she makes her pudding. ONly its no longer mud pudding its pink . Pink sheet pudding. Momma gonna make that pink sheet pudding . Ahh but I do know one thing being proven correct tastes so much better than pink sheet pudding !
It looks like April 11 was the last time we closed above 1.00. Does anyone know whether Amarin has received a delisting warning letter?
N7. Gr8 link
Thx
Kiwi
JR, Ok - I did misread / misunderstand you. My apologies for that.
JRoon,
https://fdaaa.trialstracker.net/trial/NCT02719327/
Reporting deadline is listed.
Sleven,
In January of 2022 $AMRN applied for the Lymph-Releasing Compositions and Uses thereof for Lymphatic Incorporation and Systemic Disease Treatment patent with the WIPO (World Intellectual Property Organization). The application was published on 8/3/2023 as WO2023146984A1. This application describes a new formulation and delivery system for EPA called LR-EtEPA which increases the uptake of EPA by major organs in the body.
The excipients in the formulation force the EPA to take a different pathway through the lymphatic system as opposed to the vein portal system of plain-EPA. Some of the Plain-EPA is lost as it cycles through the liver in the current delivery system.
The amount lost to some major organs like the heart, brain, lungs etc. are illustrated in this modified slide that I created. It’s possible that increased uptake in these organs can prevent diseases like Cancer’s, CKD, Dementia/Alzheimer’s, Pancreatitis etc. Claim #80 in the application has an extensive list.
Not sure if anyone has any updated info on BRAVE results being released. I had expected something by now. Starting to wonder if they will just wait until CTAD in October to release.
I wonder what the "MONKEE'S" are doing? I heard Mickey Dolenz the other day on Sirius radio. He was playing an acoustic guitar. Sounded good. We need more shows like the Monkees, some of these sitcoms are ridiculous, the writing is terrible. I can't understand why people watch these shows. Where's Seinfeld? Cheers? M.A.S.H. "Hey, hey...we're the Monkees, people trying to put us down, but, we're too busy singing, to bring anybody down." How true.
Jasbg, did you even read my post? I realize English is not your first language, but I'm not sure how you arrived at your conclusion from what I posted. Read it again, very slowly this time.
I said..."Omega-3s broadly seem to have pharmacological potential similar to that of a drug, but a risk profile more akin to a nutrient." It's too bad that Amarin can't get this point across. "- referring to Vascepa!
My point was that I appreciated how she framed the benefit of Omega-3's (strong efficacy, very low risk), but wished that Amarin would take that same tack with Vascepa.
JR, I really dont know what to think of this post ?
-----------------------------------------------------------------
Do you 'at all' - understand the Reduce-It trial - based on Vascepa - times 8 purified EPA ?
How can you seriously talk about general Omega 3 oil products in this context ?
------------------------------
You say you own 200k AMRN shares - representing an FDA approved medicine for greatly reducing risk for CDV patients !
I fail to understand how you can promote the endless number of ordinary OTC fish-oil products on the internet - being invested this BIG in AMRN and Vascepa ?
The internet can be directly filling people with BS
Fell on information below by accident searching Google:
What is the best substitute for Vascepa?
Top Vascepa alternatives and how to switch your Rx | SingleCare
The following are the most common alternatives to Vascepa.
Lovaza (omega-3-acid ethyl esters) ...
Zetia (ezetimibe) ...
Tricor (fenofibrate) ...
Lopid (gemfibrozil) ...
Niacor (niacin)
22. jan. 2023
MarketEdge: Some signs of improvement.
As of 05/14/2024 - Caution; Stock is moving Against Opinion (moving against opinion means turning positive despite negative TA indicators)
On 05/14/2024, The stock has underperformed the market when compared to the S&P 500 over the last 50 trading days. Over the last 50 trading sessions, there has been more volume on up days than on down days, indicating that AMRN is under accumulation. The stock is trading below a falling 50-day moving average which confirms the weak technical condition of AMRN. In addition, AMRN is below its falling 200-day moving average.
Hanging yourself out there FFS ...predicting breaking above the long term down trend line ( which you accurately called previously )
Good luck
Kiwi
Which is why Lovaza is so confusing. People (generally?) take it for heart health. But it misses the mark.
FFS ...should we tweet out that FFS likes AMRN ?...ala Roaring Kitty likes GME ....:--)
Kiwi
I think micro caps are under $300m mkt cap ...but agree there are features about AMRN that are micro cap "ish "
You sound almost bullish on AMRN ...am I reading you correctly ?????
Kiwi
True, I agree. Thanks for that clarification.
What is not addressed is the TA posture of the shorted stock and whether it is a micro- or macro-cap stock.
With AMRN we have fallen angel status of a micro-cap stock trading at an average volume as low as it has ever been - despite the float. That is what the elevated Days to cover is indicating (It has doubled in 1 year). This condition in effect traps shorts in a low volume situation so that if something spooks the 4%-of-the-float-herd, we will see an amplified rally that suddenly shoots prices skyward.
With beaten down small stocks like AMRN, I prefer this metric over short interest.
Anyway, that's IMO
With a larger cap stock, short interest is of more importance when expecting a squeeze.
FFS
When it comes to evaluating short positions, both the days to cover and the percentage of shares shorted (short interest) are important metrics, but they provide different insights.
Days to cover is a measure of the potential duration of a short squeeze, calculated by dividing the current short interest by the average daily trading volume. A higher days to cover ratio indicates it would take longer for short sellers to cover their positions, potentially exacerbating a short squeeze if one were to occur.
On the other hand, the percentage of shares shorted (short interest) represents the overall bearish sentiment and level of short selling activity in a stock. A high short interest percentage suggests that many investors are betting against the stock and expect the price to decline.
While both metrics are valuable, the percentage of shares shorted is generally considered more important for the following reasons:
It directly quantifies the level of short selling activity and bearish sentiment, which can be a leading indicator of potential price movements.
A high short interest percentage increases the risk of a short squeeze, as more short sellers may be forced to cover their positions if the stock price rises unexpectedly.
The days to cover ratio can be skewed by low trading volume, making it less reliable in thinly traded stocks.
Therefore, while days to cover provides insight into the potential duration of a short squeeze, the percentage of shares shorted is a more fundamental metric that directly reflects the overall short selling pressure and bearish sentiment towards a stock.
Investors typically prioritize monitoring the short interest percentage, as it is a better indicator of the potential for a significant price move, either up or down.
We ended the first quarter with a cash position of $308 million, marking a stable cash position over 7 quarters. Importantly, we also secured shareholder approval for our share repurchase program of up to $50 million. Our next step is to secure U.K. High Court approval and the share repurchases are anticipated to begin in the second quarter.
The key though is the “days to cover” (which has double over the past year).
This is due in part to both an increase of shorts, and a substantial decrease in average volume. 12 days is an attractive squeeze number.
It doesn’t take a lot of effort (volume) to ignite a squeeze. Once shorts are on the run, the stock gains attraction by virtue of its deep “fallen angel” reversal TA characteristics, making it very easy to affect a major trend reversal/run up.
Thanks for posting Lizzy. Glad that after Bhatt mentions mixed omegas that he then follows up to say that evidence for EPA is clear. Would love to have Nissen tied up in a chair and force feed him this clip on a reel.
JR, I really dont know what to think of this post ?
-----------------------------------------------------------------
Do you 'at all' - understand the Reduce-It trial - based on Vascepa - times 8 purified EPA ?
How can you seriously talk about general Omega 3 oil products in this context ?
------------------------------
You say you own 200k AMRN shares - representing an FDA approved medicine for greatly reducing risk for CDV patients !
I fail to understand how you can promote the endless number of ordinary OTC fish-oil products on the internet - being invested this BIG in AMRN and Vascepa ?
I haven't been checking in so I apologize if this has already been posted
#cardiology #cardiotwitter #cardioX #prevention @escardio https://t.co/DXCqkncUyo
— Dr. Deepak L. Bhatt (@DLBHATTMD) May 14, 2024
AMRN unlikely to be a short squeeze candidate with this low amount of short interest
Short % As of Apr-30-2024. 4%
Shares short16.18 (M)+0.34 (M)
Days to cover12.88+0.34
JMO ...
Kiwi
You need very high short positions held by master of the universe hedge fund types, to effect a GME type short squeeze.
Kiwi
True. Although there IS efficacy with mixed Omega-3's, just not necessarily for CV disease (other than Trigs).
Which is why Lovaza is so confusing. People (generally?) take it for heart health. But it misses the mark.
I have even tried educating Rhonda on the benefits of EPA-only, but she is not promoting Omega-3's strictly for CV health. She's read REDUCE-It, etc. So that's another challenge - there are benefits to Omega-3's beyond just CV health, so a lot of health professionals aren't necessarily sold on strictly EPA.
I wonder if that point is across. Docs prescribing Lovaza, docs telling people to just go out and buy omega-3’s, a whole bunch of people buying omega-3’s from the supplement industry without talking to their docs about it. Amarin needs to get people to understand the differentiation between V all those mixed omegas.
Followers
|
1111
|
Posters
|
|
Posts (Today)
|
17
|
Posts (Total)
|
426321
|
Created
|
03/12/07
|
Type
|
Free
|
Moderators ziploc_1 zmanindc golf stud Number sleven |
AMARIN TICKER RELATED LINKS
Amarin Webpage
NASDAQ AMRN Quote
Y! Finance AMRN Landing Page
Seeking Alpha AMRN Landing Page
FinViz AMRN Landing Page
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |